

Commissioner of Patents
USSN 10/661,403

AMENDMENTS TO THE SPECIFICATION

Please replace paragraph 0057 on page 13 with the following amended paragraph:

[0057] As used herein in connection with antiviral action of a material, the phrase “non-sequence complementary mode of action” indicates that the mechanism by which the material exhibits an antiviral effect is not due to hybridization of complementary nucleic acid sequences, e.g., an antisense effect. More specifically, a non-sequence complementary mode of action also means that the anti-viral activity occurs principally by a sequence-independent mode of action. Conversely, a “sequence complementary mode of action” means that the antiviral effect of a material involves hybridization of complementary nucleic acid sequences. Thus, indicating that the antiviral activity of a material is “not primarily due to a sequence complementary mode of action” means that the antiviral activity of the oligonucleotide satisfies at least one of the 4 tests provided herein (see Example, 10) for determining whether the antiviral activity is “not primarily due to a sequence complementary mode of action”. In particular embodiments, the oligonucleotide satisfies test 1, test 2, test 3, or test 4; the oligonucleotide satisfies a combination of two of the tests, i.e., tests 1 & 2; tests 1 & 3; tests 1 & 4, tests 2 & 3, tests 2 & 4, or tests 3 & 4; the oligonucleotide satisfies a combination of 3 of the tests, i.e., tests 1, 2, and 3, tests 1, 2, and 4, tests 1, 3, and 4, or tests 2, 3, and 4; the oligonucleotide satisfies all of tests 1, 2, 3, and 4.